ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IMMUCELL CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.51−0.24 (-2.23%)
Close on Oct 19, 2026
- Market cap
- $96.58M
- P/E (TTM)
- 131.4
- Dividend yield
- –
Share price
+$4.45 (+73.43%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IMMUCELL CORP /DE/ grew revenue 8.5% to $30.68M over the twelve months to Jun 30, 2026. Operating income rose 123.0% to $3.87M, moving the operating margin from 6.1% to 12.6%. Free cash flow was $4.21M, up 138.9% from a year earlier.
Revenue
$30.68M
+8.5% vs. a year earlier
Operating income
$3.87M
+123.0% vs. a year earlier
Free cash flow
$4.21M
+138.9% vs. a year earlier
EPS, diluted
$0.08
-57.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $96.58M
- P/E ratio
- 131.4
- Price to sales
- 3.15
- Price to book
- 3.08
- Dividend yield
- –
- Free cash flow yield
- 4.36%
Fundamentals
- Revenue
- $30.68M
- Net income
- $787.37K
- EPS, diluted
- $0.08
- Free cash flow
- $4.21M
- Book value per share
- $3.41
- Diluted shares
- 9M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$30.68M+8.5% YoY
Gross profit
$12.37M+16.8% YoY
Operating income
$3.87M+123.0% YoY
Net income
$787.37K-55.3% YoY
EPS, diluted
$0.08-57.9% YoY
Free cash flow
$4.21M+138.9% YoY
Reported periodTrailing twelve months